Jam

Society Pass (SOPA) announced it has regained compliance with Nasdaq listing standards, specifically Rule 5550(b)(2), by meeting the minimum stockholders’ equity requirement of $2.5 million. Nasdaq confirmed the compliance on September 2, 2025. Maintaining its Nasdaq listing is crucial for SOPA, a Southeast Asian investment firm, as it allows continued access to capital markets and enhances its visibility among investors in the competitive tech landscape. This follows previous scrutiny regarding its listing status.

Medical Care Technologies Inc. (MDCE) CEO Marshall Perkins surrendered 680 million shares, decreasing the outstanding share count. While the authorized share count remains at 8 billion, this action signals commitment to shareholder value. MDCE focuses on AI healthcare and sports authentication through subsidiaries, targeting the trillion-dollar global healthcare market with its AI health diagnostics platform. The move aims to strengthen the company’s financial foundation and enable continued growth.

Planet Labs PBC (PL) reported record Q2 revenue of $73.4M, a 20% YoY increase, and a 516% YoY increase in RPOs to $690.1M. Backlog grew 245% YoY to $736.1M. The company generated $85.1M in year-to-date net cash from operating activities and $54.3M in positive free cash flow. Planet launched two high-resolution Pelican satellites and secured key contracts with the U.S. DoD, NATO, and the German government. They ended the quarter strong with revenue growth, positive EBITDA, and $271.5M in cash, cash equivalents, and short-term investments.

Focus Graphite (FCSMF) Chairman Jeff York converted C$200,000 of his personal loan into company equity, representing 571,428 shares. This conversion is part of an initiative to eliminate York’s total loan of C$1,535,000 and improve the company’s financial standing. To adhere to TSX Venture Exchange regulations, York sold 488,000 shares. The company intends to continue converting debt to equity strategically to protect shareholder value and propel the advancement of the Lac Knife and Lac Tetepisca graphite projects.

Apex Critical Metals (APXCF) appointed Alex Knox to its Technical Advisory Board, enhancing expertise in rare earth elements and niobium. The company granted 1,760,000 stock options to directors, officers, and consultants, exercisable at $1.97 until 2030, vesting over 12 months. Apex also issued 1,660,000 restricted share units (RSUs) that vest after four months, but can be deferred to quarterly vesting over 16 months. These incentives aim to align management interests with shareholders.

Alcon will showcase its latest advancements in cataract, refractive, and glaucoma technologies at the upcoming ESCRS in Copenhagen. Key highlights include the European launch of UNITY VCS, Clareon Vivity IOL, and Voyager DSLT. Alcon will present over 40 studies, focusing on Vivity IOL outcomes, the CENTURION system’s performance, and Wavelight plus data demonstrating superior refractive outcomes compared to SMILE for myopia correction. These innovations and data aim to strengthen Alcon’s position and expand its market share in Europe.

Faraday Future (FFAI) will host its 919 event showcasing the FX Super One and its crypto initiatives. The event includes updates on homologation, Middle East launch plans, and details about the C10 Treasury. CEO YT Jia recently purchased $180,000 in FFAI stock, signaling confidence. FFAI also allocated $2 million to its crypto treasury, focusing on BNB and LINK, and initiated staking. Shareholders will vote on proposals, including increasing shares for equity incentives.

Innovent Biologics presented positive Phase 2 results for tigulixostat (IBI128), a xanthine oxidase inhibitor for gout, at APLAR 2025. The study (NCT06501534) in Chinese patients showed tigulixostat significantly reduced serum uric acid levels compared to febuxostat, with a favorable safety profile and no serious adverse events. Innovent plans to initiate Phase 3 trials in China in the second half of 2025, aiming to address the unmet need for safer and more effective gout treatments amidst concerns about existing therapies.

Dianthus Therapeutics (DNTH) will report topline results from its Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) on September 8, 2025, at 8:00 a.m. EDT. The clinical-stage biotech company, focused on antibody complement therapeutics for autoimmune diseases, will host a conference call and webcast with a Q&A session. Investors can access the webcast via the company’s investor relations website, with a replay available afterward. Claseprubart targets the classical complement pathway, potentially offering a targeted gMG treatment.

IDEAYA Biosciences and Hengrui Pharma presented Phase 1 trial data for IDE849 (SHR-4849), a DLL3-targeting TOP1 ADC, in advanced Small Cell Lung Cancer (SCLC). Across all SCLC lines, the Overall Response Rate (ORR) was 73.2% with a median Progression-Free Survival (PFS) of 6.7 months. In 2nd-line SCLC, the ORR was 77.1%, with median PFS not reached. Notably, patients with brain metastases showed a confirmed ORR of 66.7%. The safety profile was manageable. This data suggests IDE849 has a potential best-in-class profile and warrants further clinical development.